KLOW is a research-formulated injectable blend designed specifically for experimental and non-therapeutic laboratory settings. Unlike single-compound peptides, KLOW combines the activity of three distinct peptides into one preparation: BPC-157, TB-500, and GHK-Cu. Each of these peptides has been individually studied in preclinical models, and the KLOW blend brings them together in a single bacteriostatic solution for ease of investigative use.

This multi-peptide formulation is intended for researchers examining complementary biological pathways such as connective-tissue repair, cellular signaling, and recovery mechanisms. The combination approach allows laboratories to explore synergistic effects without the need to handle and reconstitute each peptide separately.

Analytical handling guidelines and quality standards are applied to every KLOW batch to ensure consistency prior to distribution.

Intended Use: Product supplied strictly as an investigational research compound. It is not approved by the FDA, TGA, or any regulatory authority for therapeutic, diagnostic, or medicinal use. Not for human or animal consumption.